Jane Street Group LLC Decreases Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Jane Street Group LLC reduced its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 61.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,958 shares of the company’s stock after selling 39,583 shares during the period. Jane Street Group LLC’s holdings in Aura Biosciences were worth $222,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Long Focus Capital Management LLC lifted its holdings in Aura Biosciences by 113.4% in the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after purchasing an additional 561,766 shares in the last quarter. Wellington Management Group LLP acquired a new position in Aura Biosciences during the third quarter worth about $1,037,000. Bank of New York Mellon Corp grew its stake in Aura Biosciences by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock valued at $1,081,000 after acquiring an additional 48,549 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Aura Biosciences by 20.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock valued at $1,892,000 after acquiring an additional 41,711 shares during the last quarter. Finally, State Street Corp lifted its stake in Aura Biosciences by 3.7% in the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after purchasing an additional 26,841 shares in the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Stock Performance

Shares of AURA stock opened at $7.60 on Monday. The firm has a market cap of $379.63 million, a P/E ratio of -4.39 and a beta of 0.30. The firm’s 50 day moving average price is $8.92 and its 200-day moving average price is $8.89. Aura Biosciences, Inc. has a one year low of $6.63 and a one year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02. As a group, research analysts predict that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AURA has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a report on Thursday, November 14th. Scotiabank lifted their price target on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Finally, BTIG Research lifted their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Aura Biosciences has a consensus rating of “Buy” and a consensus target price of $23.00.

Insider Buying and Selling at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.04, for a total transaction of $300,903.68. Following the sale, the insider now owns 329,847 shares of the company’s stock, valued at approximately $3,971,357.88. This represents a 7.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Julie B. Feder sold 25,131 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the sale, the chief financial officer now owns 134,276 shares in the company, valued at approximately $1,615,340.28. The trade was a 15.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 79,081 shares of company stock valued at $891,353 in the last three months. 5.40% of the stock is owned by corporate insiders.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.